Konuşmacılar

Konuşmacılar/Başkanlar*

  • Janet Abrahm, MC, FACP, FAAHPM, Division Chief, Adult Palliative Care, Dana Farber Cancer Institute/ Associate Professor of Medicine, Harvard Medical School, USA
  • Dirk Arnold, Professor of Medicine, Medical Director, University Comprehensive Cancer Center, University Hospital Eppendorf, GERMANY
  • Paul Baas, Netherlands Cancer Institute, THE NETHERLANDS
  • Harry Bartelink, Radiation Oncologist, Division of Radiotherapy, The Netherlands Cancer Institute, THE NETHERLANDS
  • Adrian Begg, Group Leader, Netherlands Cancer Institute, Amsterdam, THE NETHERLANDS
  • José Belderbos, Radiation Oncologist, The Netherlands Cancer Institute, THE NETHERLANDS
  • Magnus Bjorkholm, Professor,Head of Unit, Unit of Internal Medicine, Karolinska Institutet ,SWEDEN
  • Bernardo Bonanni, MD, Director, Division of cancer Prevention and Genetics, European Institute of Oncology, ITALY
  • Jean Bourhis, Professor, Head of Radiation Oncology Department, Institute Gustave Roussy, FRANCE
  • William Breitbart, Chief Psychiatry Service, Department of Psychiatry & Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York,USA
  • Alan Burnett, Cardiff University, UNITED KINGDOM
  • Fatima Cardoso, Head, Breast Cancer Unit & Breast Cancer Research Director, Champalimaud Cancer Center, Lisbon, PORTUGAL
  • Peter Carroll, MD, MPH, Professor and Chair, UCSF Department of Urology/ Ken and Donna Derr – Chevron Distinguished Professor, Associate Dean, UCSF School of Medicine/ Director of Clinical Services & Strategic Planning, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA
  • Elisabeth E. G. De Vries, Medical Oncologist, Department of Medical Oncology, University Medical Center Groningen, THE NETHERLANDS
  • Steven DeMeester, Associate Professor of Cardiothoracic Surgery, University of Southern California, USA
  • Volker Diehl, Professor of Medicine, University of Cologne, GERMANY
  • Eleni Efstathiou, Adjunct Assistant Professor, Genitourinary Medical Oncology, MD Anderson Cancer Center, Houston, USA
  • Prof Alexander Eggermont, General Director, Cancer Institute Gustave Roussy, FRANCE
  • Dominique Elias, MD, PhD, Chef du Département de Chirurgie Générale, Institut Gustave Roussy, FRANCE
  • Paul Ellis, Guy’s Hospital, Dept. of Medical Oncology, London, UNITED KINGDOM
  • Andreas Engert, Chairman, German Hodgkin Study Group/ Professor of Internal Medicine, Hematology & Oncology, Department of Internal Medicine I, University Hospital of Cologne, GERMANY
  • Keith Flaherty, M.D., Director of Developmental Therapeutics, Massachusetts General Hospital Cancer Center, USA
  • Silvia Formenti, M.D., Professor and Chairman, Department of Radiation Oncology, New York University School of Medicine, USA
  • Alain Fourquet, Department of Radiation Oncology, Institut Curie, FRANCE
  • Evanthia Galanis, Mayo Clinic, USA
  • Andrea Gallamini, Head, Hematology Department and Bone Marrow Transplant Unit, Az. Ospedaliera S. Croce e Carle, ITALY
  • Randy Gascoyne, Hematopathologist, Clinical Professor, British Columbia Cancer Agency, Vancouver, CANADA
  • Theodore Girinsky, Department of Radiation Oncology, Institut Gustave Roussy, FRANCE
  • Olivier Glehen, Professor of Surgical Oncology, Centre Hospitalier LYON-SUD, FRANCE
  • David Goldenberg,  Professor and President, Garden State Cancer Center, New Jersey, USA
  • Marcia Hall, Mount Vernon Cancer Centre, UK
  • Philip Harter, Department of Gynecology & Gynecologic Oncology, HSK, Dr. Horst Schmidt Klinik Wiesbaden, GERMANY
  • Kelvin Hong, Assistant Professor of Radiology and Surgery, Division of Vascular and Interventional Radiology, Fellowship Program Director, Johns Hopkins Medical Institutions, Baltimore, USA
  • Stephen Johnston, Professor of Breast Cancer Medicine, Consultant Medical Oncologist & Director of Clinical Research & Development, Royal Marsden Hospital & Institute of Cancer Research, UNITED KINGDOM
  • Terry Jones, Director, PET Research Advisory Company, UK
  • Prof Scott Kopetz, MD, PhD, Assistant Professor, Gastrointestinal Medical Oncology, M.D. Anderson Cancer Center, USA
  • Robert J. Kurman, M.D., Director, Primary Appointment In Gynecology and Obstetrics, Secondary Appointment In Pathology, Division of Gynecologic Pathology, Johns' Hopkins Hospital, Baltimore, USA
  • James Larkin, Consultant Medical Oncologist, Royal Marsden Hospital, London, UK
  • Jonathan Ledermann, Director & Professor of Medical Oncology, UCL Cancer Research UK Centre, UNITED KINGDOM
  • Edward Leen, Professor of Radiology, Imperial College London, UK
  • Christopher Logothetis, Chairman / Professor, Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, USA
  • Peter Malfertheiner, Professor of Medicine and Chairman, Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University, GERMANY
  • J. Gordon Mc Vie, MD, FRCP, FRCS Ed, FMedSci, DSc(Hon), Senior Consultant, Scientific Directorate, European Institute of Oncology, ITALY
  • Cornelis Melief, Professor of Immunology, Leiden University Medical Center, THE NETHERLANDS
  • Gary Middleton, Royal Surrey County Hospital NHS Foundation Trust, UK
  • Emmanuel Mitry, Head of medical oncology departement, Institut Curie – Hopital Huguenin, FRANCE
  • Brendan Moran, Consultant General and Colorectal Surgeon, Basingstoke and North Hampshire Hospital, UNITED KINGDOM
  • Bernard Nordlinger, Surgical Oncologist, Hopital Ambroise Pare, CHU Paris Ouest, Boulogne, FRANCE
  • Kjell Öberg, Professor, Consultant, Department of Medical Sciences, Uppsala University/ Department of Endocrine Oncology, Uppsala University Hospital, SWEDEN
  • Ken O’Byrne, Consultant Medical Oncologist, St’ James Hospital, Dublin, IRELAND
  • Roberto Orecchia, European Institute of Oncology, ITALY
  • Angelo Paradiso, MD, PhD, Scientific Director, National Cancer Center, Bari, ITALY
  • Giorgio Parmiani, Head, Unit of Immuno-Biotherapy of Melanoma and Solid Tumors, San Raffaele Scientific Institute, Milan, ITALY
  • Pompiliu Piso, Surgical Oncologist, Department for Surgery, University of Regensburg, GERMANY
  • Sanjay Popat, Clinical Senior Lecturer, Imperial College, London, UNITED KINGDOM
  • Rick Popert, Consultant urological surgeon and lead clinician, Guy’s and St’ Thomas NHS Foundation Trust, London, UNITED KINGDOM
  • Graeme J Poston, Divisional Director of Surgery, Digestive Diseases, Critical Care and Anaesthesia, Aintree University Hospitals NHS Foundation Trust, UK
  • Pat Price, Visiting Professor of Oncology, Imperial College London, UK
  • Kathleen Pritchard, Senior Scientist, Professor of Medicine, Medical Oncologist, Sunnybrook Odette Cancer Centre, University of Toronto, CANADA
  • Eric Raymond, Professor, Service Inter-Hospitalier De Gastenterologie Bichat-Beaujon, Hopital Beaujon, FRANCE
  • David Reardon, Clinical Director of the Center for Neuro-Oncology, Dana Farber Cancer Institute, Boston, USA
  • Nicholas Reed, Consultant in Clinical Oncology, Beatson Oncology Centre, Scotland, UK
  • Peter Schlag, Director, Charite' Comprehensive Cancer Center, GERMANY
  • Padmanee Sharma,  Associate Professor, MD Anderson Cancer Center, USA
  • Astrid T. Stormorken, Consultant in Cancer Genetics at The Royal Marsden Hospital, London, UK
  • Tom Treasure, Professor of Cardiothoracic Surgery, University College London, UK
  • Marc Van de Vijver, Department of Pathology, Netherlands Cancer Institute, THE NETHERLANDS
  • John Wagstaf, MD, MB ChB, FRCP (London), South West Wales Cancer Institute & Swansea School of Medicine, Singleton Hospital, Swansea, UK
  • Patrick Y. Wen, Director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, USA
  • Anders Wennborg, MD, PhD, Medical Director, Affibody AB, SWEDEN
  • Norman Wolmark, Chairman, NSABP, Pittsburg, USA
  • John Yarnold, Professor of Clinical Oncology, Institute of Cancer Research, UΚ

*17 Haziran 2011 tarihinde onaylandığı haliyle